Novel pharmacological treatments for heart failure

Expert Opinion on Investigational Drugs

Volumn 12, Issue 11, 2003, Pages 1791-1801

  Tang, W H Wilson ^a   Francis, Gary S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Drug development; Heart failure; Therapy

Indexed keywords

3 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)BICYCLO[2.2.2]OCTAN 1 YL]PROPIONIC ACID; ADENOSINE RECEPTOR BLOCKING AGENT; ADENTRI; BISOPROLOL; BOSENTAN; BUCINDOLOL; CANDESARTAN; CARVEDILOL; CONIVAPTAN; DARUSENTAN; ENALAPRIL; ENOXIMONE; ENRASENTAN; EPLERENONE; ETANERCEPT; IBOPAMINE; LEVOSIMENDAN; METOPROLOL; MILRINONE; MOXONIDINE; NAXIFYLLINE; NEBIVOLOL; NESIRITIDE; OMAPATRILAT; OXIPURINOL; SPIRONOLACTONE; SR 121463B; TOLVAPTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VASOPRESSIN RECEPTOR ANTAGONIST;

ACUTE HEART FAILURE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE MARKER; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; GYNECOMASTIA; HUMAN; IMMUNOMODULATION; LONG QT SYNDROME; NONHUMAN; RELIABILITY; REVIEW; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANTI-INFLAMMATORY AGENTS; CARDIOTONIC AGENTS; CARDIOVASCULAR AGENTS; CLINICAL TRIALS; DRUG DESIGN; HEART FAILURE, CONGESTIVE; HORMONE REPLACEMENT THERAPY; HUMANS; NEUROTRANSMITTER AGENTS; PHOSPHODIESTERASE INHIBITORS;

EID: 0242659103     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.11.1791     Document Type: Review

References (93)

1. AMERICAN HEART ASSOCIATION: Heart and Stroke Statistics - 2003 Update. American Heart Association, Dallas , TX, USA (2002).
2. LLOYD-JONES DM, LARSON MG, LEIP EP et al.: Lifetime risk for developing congestive heart fialure: the Framingham Heart Study. Circulation (2002) 106:3068-3072.
3. PACKER M: The impossible task of developing a new treatment for heart failure. J. Card. Fail. (2002) 8:193-196.
4. MEHRA MR, UBER PA, FRANCIS GS: Heart failure therapy at a crossroad: are there limits to the neurohormonal model? J. Am. Coll. Cardiol. (2003) 41:1606-1610.
5. KALRA PR, MOON JC, COATS AJ: Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int. J. Cardiol. (2002) 85:195-197.
6. ABRAHAM WT: Enrasentan Cooperative Randomized Evaluation (ENCOR). American College of Cardiology 50th Annual Scientific Session, Atlanta, GA, USA (2001).
7. ANAND I, LUSCHER TF: The EARTH trial. XXIV Congress of the European Society of Cardiology, Berlin, Germany (2002).
8. OMAPATRILAT CARDIOVASCULAR TREATMENT ASSESSMENT VERSUS ENALAPRIL (OCTAVE): To compare the efficacy and safety of omapatrilat against enalapril in the treatment of hypertension. American College of Cardiology 51st Annual Scientific Session, Atlanta, GA, USA (2002).
9. PACKER M, CALIFF RM, KONSTAM MA et al.: Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulasion (2002) 106:920-926.
10. COATS AJ: Heart failure 99 - the MOXCON story. Int. J. Cardiol. (1999) 71:109-111.
11. BETA-BLOCKER EVALUATION AND SURVIVAL TRIAL INVESTIGATORS: A trial of the beta-blocker bucindolol in patients with advanced heart failure. N. Engl. J. Med. (2001) 344:1659-1667.
12. COHN JN, TOGNONI G, THE VALSARTAN HEART FAILURE TRIAL INVESTIGATORS: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl. J. Med. (2001) 345:1667-1675.
13. GRANGER CB, McMURRAY JJ, YUSUF S et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet (2003) 362:772-776.
14. McMURRAY JJ, OSTERGREN J, SWEDBERG K et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 362:767-771.
15. PFEFFER MA, McMURRAY J, LEIZOROVICZ A et al.: Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am. Heart J. (2000) 140:727-734.
16. PITT B, REMME W, ZANNAD F et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348:1309-1321.
17. PITT B, ZANNAD F, REMME WJ et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. (1999) 341:709-717.
18. WEBER KT: Aldosterone in congestive heart failure. N. Engl. J. Med. (2001) 345:1689-1697.
19. ROCHA R, WILLIAMS GH: Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs (2002) 62:723-731.
20. KRUM H, NOLLY H, WORKMAN D et al.: Efficacy of eplerenone added to reninangiotensin blockade in hypertensive patients. Hypertension (2002) 40:117-123.
21. WEINBERGER MH, RONIKER B, KRAUSE SL, WEISS RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. (2002) 15:709-716.
22. TANG WH, VAGELOS RH, YEE YG et al.: Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J. Am. Coll. Cardiol. (2002) 39:70-78.
23. PITT B, REICHEK N, WILLENBROCK R et al.: Effects of eplerenone, enalapril, and eplerenone/ enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation (2003) 108:1831-1838.
24. ZANNAD F, ALLA F, DOUSSET B, PEREZ A. PITT B: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). RALES Investigators. Circulation (2000) 102:2700-2706.
25. GRANDI AM, IMPERIALE D, SANTILLO R et al.: Aldosterone antagonist improve diastolic function in essential hypertension. Hypertension (2002) 40:647-652.
26. GOLDSMITH SR: Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure. Congest. Heart Fail. (2002) 8:251-256.
27. YATSU T, TOMURA Y, TAHARA A: Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur. J. Pharmacol. (1999) 376:239-246.
28. NAITOH M, SUZUKI H, MURAKAMI M: Effects of oral AVP receptor antagonists OPC21268 and OPC31260 on congestive heart failure in conscious dogs. Am. J. Physiol. (1994) 267:H2245-H2254.
29. RUSSELL SD, SELARU P, PYNE DA et al.: Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation ofa Vasopressin Antagonist in CHF patient, undergoing Exercise) trial. Am. Heart J. (2003) 145:179-186.
30. GHEORGHIADE M, NIAZI I, OUYANG J et al.: Visopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation (2003) 107:2690-2696.
31. GHEORGHIADE M, GATTIS WA. BARBAGELATA A et al.: Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes ofpatients hospitalized with worsening congestive heart failure. Am. Heart J. (2003) 145:S51-S54.
32. GOTTLIEB SS: Renal effects of adenosine A1-receptor antagonists in congestive heart failure. Drugs (2001) 61:1387-1393.
33. LUCAS DG Jr, PATTERSON T, HENDRICK JW et al.: Effects of adenosine receptor subtype A1 on ventricular and renal function. J. Cardiovasc. Pharmacol. (2001) 38:618-624.
34. GOTTLIEB SS, SKETTINO SL, WOLFF A et al.: Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patientse with congestive heart failure. J. Am. Coll. Cardiol. (2000) 35:56-59.
35. GOTTLIEB SS, BRATER DC, THOMAS I et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation (2002) 105:1348-1353.
36. MILLS RM, HOBBS RE, YOUNG JB: BNP for heart failure: role of nesiritide in cardiovascular therapeutics. Congest. Heart Fail (2002) 8:270-273.
37. PUBLICATION COMMITTEE FOR THE VMAC INVESTIGATORS (VASODILATATION IN THE MANAGEMENT OF ACUTE CHF): Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA (2002) 287:1531-1540.
38. BURGER AJ, ELKAYAM U, NEIBAUR MT: Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart filure receiving dobutamine versus nesiritide therapy Am. J. Cardiol. (2001) 88:35-39.
39. SACKNER-BERNSTEIN J, KOWALSKI M, FOX M: Is there risk associated with the use of nesiritide for acute heart failure? J. Am. Cell. Cardiol. (2003) 41:161A (Abstract 1085-70).
40. POOLE-WILSON PA, SWEDBERG K, CLELAND JGF et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 362:7-13.
41. POOLE-WILSON PA: Clinical trials update II (Heart Failure) - the Carvedilol Or Metoprolol European Trial (COMET). European Society of Cardiology Congress 2003, Vienna, Austria (2003).
42. MERIT-HF INVESTIGATORS: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353:2001-2007.
43. [NO AUTHORS LISTED]: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (2001) 353:9-13.
44. OTTERSTAD JE, FORD I: The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurtent myocardial infarction in CAPRICORN compare with previous beta-blocker trials? Eur. J. Heart Fail. (2002) 4:501-506.
45. McNEELY W, GOA K: Nebivolol in the management of essential hypertension. A review. Drugs (1999) 57:633-651.
46. SHIBATA MC, FLATHER MD, BOHM M et al.: Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and design. Int. J. Cardiol. (2002) 86:77-85.
47. RAJFER SI, DAVIS FR: Role of dopamine receptors and the utility of dopamine agonists in heart failure. Circulation (1990) 82:I97-1102.
48. HAMPTON JR, VAN VELDHUISEN DJ, KLEBER FX et al.: Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lance (1997) 349:971-977.
49. TJEERDSMA G, VAN WIJK LM, MOLHOEK GP et al.: Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure. Cardiovasc. Drug Ther. (2001) 15:139-145.
50. FIGGITT DP, GILLIES PS, GOA KL: Levosimendan. Drugs (2001) 61:613-627.
51. CLELAND JG, McGOWAN J: Levosimendan: a new era for inodilator therapy for heart failure Curr. Opin. Cardiol. (2002) 17:257-265.
52. KIVIKKO M, LECHTONEN L, COLUCCI WS: Sustained hemodynamic effects of levosimendan. Circulation (2003) 107:81-86.
53. AJIRO Y, HAGIWARA N, KATSUBE Y, SPERELAKIS N, KASANUKI H: Levosimendan increases L-type Ca(2+) curient via phosphodiesterase-3 inhibition in human cardiac myocytes. Eur. J. Pharmacol. (2002) 435:27-33.
54. FOLLATH F, CLELAND JGF, JUST H: Efficacy and safety of intravenous levosimendan, a novel calcium sensitiser, in severe low output failure. Lancet (2002).
55. MOISEYEV VS, PODER P, ANDREJEVS N et al.: Randomized study on safety and effectiveness of levosimendan in patients with left ventricular heart failure after an acute myocardial infarction (the RUSSLAN study). Eur. Heart J. (2002) 23(18):1422-1432.
56. MANN DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. (2002) 91:988-998.
57. KRUM H: Tumor necrosis fwtor-α blockade as a therapeutic strategy in heart failure (RENEWAL and ATTACH): unsuccessful, to be specific. J. Card. Fail. (2002) 8:365-368.
58. TORRE-AMIONE G: Immune modulation therapy reduces death and hospitalization in class III/IV heart failure patients: results of a randomized clinical trial. American Heart Association 75th Annual Scientific Sessions, Chicago, II, USA. Circulation (2002) 106:II-469 (Abstract 2324).
59. NODE K, FUJITA M, KITAKAZE M et al.: Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation (2003) 108:839-843.
60. FARQUHARSON CA, BUTLER R, HILL A, BELCH JJ, STRUTHERS AD: Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation (2002) 106:221-226.
61. CAPPOLA TP, KASS DA, NELSON GS et al.: Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation (2001) 104:2407-2411.
62. VASAN S, FOILES PG, FOUNDS HW: Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. Expert Opin. Investig. Drugs (2001) 10:1977-1987.
63. KASS DA, SHARPRIO EP, KAWAGUCHI M et al.: Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation (2001) 104:1464-1470.
64. OLDFIELD MD, BACH LA. FORBES JM et al.: Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J. Clin. Invest. (2001) 108:1853-1863.
65. SCHOFIELD RS, HILL JA: The use of ranolazine in cardiovascular disease. Expert Opin. Investig. Drugs (2002) 11:117-123.
66. CHANDLER MP, STANLEY WC, MORITA H et al.: Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ. Res. (2002) 91:278-280.
67. PEPINE CJ, WOLFF AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am. J. Cardiol. (1999) 84:46-50.
68. RUPP H, ZARAIN-HERZBERG A. MAISCH B: The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz (2002) 27:621-636.
69. SABBAH HN, CHANDLER MP, MISHIMA T et al.: Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J. Card. Fail. (2002) 8:416-422.
70. BRISTOW M: Etomoxir: a new approach to treatment of chronic heart failure. Lancet (2000) 356:1621-1622.
71. SCHMIDT-SCHWEDAS, HOLUBARSCH C: First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin. Sci. (Lond) (2000) 99:27-35.
72. RUPP H, JACOB R: Metabolically-modulated growth and phenotype of the rat heart. Eur. Heart J. (1992) 13(Suppl. D):56-61.
73. NIKOLAIDIS LA, SOKOS GG, MANKAD SV et al.: GLP-1 improves clinical and functional performance in patients with advanced heart failure. Heart Failure Society of America 7th Annual Scientific Meeting, Las Vegas, NV, USA. J. Card. Fail. (2003) 9:S9.
74. HAMILTON MA, STEVENSON LW, FORANOW GC et al.: Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure Am. J. Cardiol. (1988) 81:443-447.
75. PENNOCK GD, RAVA TE, BAHL JJ, GOLDMAN S, MORKIN E: Combination treatment with captopril and the thyroid hormone analogue, 3,5-diiodothyropropionic acid. A new approach to improve left ventricular performance in heart failure Circ. J. (1993) 88:1289-1298.
76. MORKIN E, PENNOCK GD, SPOONER PH et al.: Pilot studies on the use of 35-diiodothyropropionic acid, a thyroid hormone analog, in the treatment of congestive heart failure. Cardiology (2002) 97:218-225.
77. FAZIO S, SABATINI D, CAPALDO B et al.: A preliminary study of growth hormone in the treatment of dilated cardiomyopathy N. Engl. J. Med. (1996) 334:809-814.
78. JENKINS RC, ROSS RJ: The growth hormone IGF-I axis in dilated cardiomyopathy. Clin. Endocrinol. (Oxf.) (1999) 50:415-416.
79. OSTEZIEL KJ, STROHM O, SCHULER J et al.: Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated catdiomyopathy. Lancet (1998) 351:1233-1237.
80. SILVERBERG DS, WEXLER D, IAINA A: The importance of anemia and its correlation in the management of severe congestive heart failure. Eur. J. Heart Fail. (2002) 4:681-686.
81. DONNE RL, FOLEY RN: Anaemia management and cardiomyopathy in renal failure. Nephrol. Dial. Transplant. (2002) 17:37-40.
82. SILVERBERG DS, WEXLER D, BLUM M et al.: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J. Am. Coll. Cardiol. (2000) 35:1737-1744.
83. SILVERBERG DS, WEXLER D, SHEPS D et al.: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. cardiol. (2001) 37:1775-1780.
84. PERROT A, OSTERZIEL KJ, BECK M, DIETZ R, KAMPMANN C: Fabry disease: focus on cardiac manifestations and molecular mechanisms. Herz (2002) 27:699-702.
85. MACDERMOT KD, HOLMES A, MINERS AH: Anderson-Fabry disease: clinical manifestations and impact on disease in a cohort of 98 hemizygote males. J. Med. Genet. (2001) 38:750-760.
86. ENG CM, GUFFON N, WELCOX WK: Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N. Engl. J. Med. (2001) 345:9-16.
87. SCHIFFMANN R, KOPP JB, AUSTIN HA: Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA (2001) 285:2743-2749.
88. YUSUF S, PITT B: A lifetime of Prevention: the case of heart failure. Circulation (2002) 106:2997-2998.
89. YUSUF S, SLEIGHT P, POGUE J et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. (2000) 342:145-153.
90. (NO AUTHORS LISTED): Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet (2000) 355:253-259.
91. DAHLOF B, DEVEREUX RB, KJELDSEN SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:995-1003.
92. FOX KM: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind placebo-controlled, multicentre trial (the EUROPA study). Lancet (2003) 362:782-788.
93. HUNT SA. BAKER DW, CHIN MH et al.: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. (2001) 38:2101-2113.